Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Stigma Reduction Intervention for MSM and Healthcare Providers

13 de novembro de 2026 atualizado por: Toan Ha, University of Pittsburgh

Adapting an Intervention to Reduce Stigma Among MSM and Healthcare Providers in Vietnam

This study describes only the Aim 2 clinical trial component of the NIH-funded project "Adapting an Intervention to Reduce Stigma among MSM and Healthcare Providers in Vietnam". The purpose of this pilot randomized waitlist-controlled trial (N=180) is to evaluate the preliminary efficacy of DONGHANH, a stigma-reduction intervention for men who have sex with men and healthcare providers in Vietnam. The study will provide preliminary data on the intervention's potential impact to inform the design of a larger future trial evaluating its effects on HIV prevention and care outcomes in Vietnam and in other countries with collectivist cultures.

Visão geral do estudo

Status

Ainda não está recrutando

Condições

Intervenção / Tratamento

Descrição detalhada

This is a pilot randomized waitlist-controlled trial of DONGHANH, a stigma-reduction intervention for men who have sex with men (MSM) and healthcare providers (HCP) in Vietnam. Participants are randomized 1:1 to receive DONGHANH immediately or to a waitlist control. Waitlist participants receive the same DONGHANH workshops after the 3-month assessment. Assessments occur at baseline and 3 months for all participants. Participants in the immediate intervention arm complete an additional assessment at 6 months. Efficacy outcomes are analyzed using generalized linear mixed models or generalized estimating equations, with the intervention-by-time interaction as the primary test of effect.

Tipo de estudo

Intervencional

Inscrição (Estimado)

180

Estágio

  • Não aplicável

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Toan Ha, MD, DrPH
  • Número de telefone: 412-383-4576
  • E-mail: toh33@pitt.edu

Locais de estudo

      • Hanoi, Vietnã
        • Institute of Social and Medical Studies
        • Contato:
          • Nam T Nguyen, MD, DrPH
          • Número de telefone: +84-02435558288
          • E-mail: ntnam@isms.org.vn

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

MSM:

  • Age 18 years or older
  • Cisgender male
  • HIV-positive, HIV-negative, or unknown HIV status
  • Self-reported history of condomless sex
  • Able to provide written informed consent

Healthcare providers:

  • Age 18 years or older
  • Works in an HIV outpatient clinic or community-based organization clinic in Hanoi
  • Able to provide informed consent

Exclusion Criteria:

  • Unable to provide informed consent
  • Unable to read and understand Vietnamese
  • Currently enrolled in another HIV intervention study.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: DONGHANH Intervention

DONGHANH is a stigma-reduction intervention for men who have sex with men (MSM) and healthcare provider (HCP) in Vietnam. The intervention is delivered through five workshops attended jointly by MSM and HCP participants. Each workshop lasts approximately 1.5 days and consists of 10 modules. The modules use presentations, group discussions, and interactive exercises to build understanding of HIV-related and sexuality-related stigma; facilitate the sharing of personal experiences of stigma among MSM and HCP participants; explore the health effects of stigma; and develop strengths and strategies for coping with and reducing stigma.

DONGHANH is a culturally adapted, group-based patient-provider stigma-reduction workshop for men who have sex with men (MSM) and healthcare providers (HCP) in Hanoi. The workshop brings together MSM and HCP for about 1.5 days across 10 modules covering understanding stigma, intersecting stigmas and their outcomes, HIV knowledge, coping with and changing stigma, and developing stigma-reduction tools. It is led by 3 trained facilitators (1 MSM, 1 HCP, 1 co-facilitator) and uses presentations, exercises, small-group work, and group presentations. Participants also contribute suggestions to contents of a supplementary e-module (website) conveying information about stigma and stigma reduction strategies.

Experimental: Waitlist control group

Participants in this arm receive no intervention for the first 3 months after randomization. During this period, study staff contact them every 2 weeks to maintain retention. These contacts do not include any intervention content. After the 3-month assessment, participants receive the same DONGHANH workshops Assessments occur at baseline, 3 months and 6 months

DONGHANH is a culturally adapted, group-based patient-provider stigma-reduction workshop for men who have sex with men (MSM) and healthcare providers (HCP) in Hanoi. The workshop brings together MSM and HCP for about 1.5 days across 10 modules covering understanding stigma, intersecting stigmas and their outcomes, HIV knowledge, coping with and changing stigma, and developing stigma-reduction tools. It is led by 3 trained facilitators (1 MSM, 1 HCP, 1 co-facilitator) and uses presentations, exercises, small-group work, and group presentations. Participants also contribute suggestions to contents of a supplementary e-module (website) conveying information about stigma and stigma reduction strategies.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Feasibility of the intervention
Prazo: 3 months

Feasibility of the intervention will be assessed with the feasibility of intervention measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The score is the mean of the four items, with a minimum of 1 and a maximum of 5. Higher scores indicate greater perceived feasibility. Results will be reported separately for among MSM and healthcare providers.

3 months
Acceptability of of the intervention
Prazo: 3 months

Acceptability of the intervention will be assessed with the acceptability of intervention measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The score is the mean of the four items, with a minimum of 1 and a maximum of 5. Higher scores indicate greater acceptability. Results will be reported separately for MSM and healthcare providers.

3 months
Appropriateness of the intervention
Prazo: 3 months

Appropriateness of the intervention will be assessed using the intervention appropriateness measure, a 4-item scale. Each item is rated from 1 (completely disagree) to 5 (completely agree). The overall score is calculated as the mean of the four items, ranging from 1 to 5. Higher scores indicate greater perceived appropriateness. Results will be reported separately for MSM and healthcare providers.

3 months

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Changes in stigma
Prazo: Baseline, 3 months, and 6 months

Change in stigma will be measured using the homosexuality-related stigma scale (Vietnamese version), a self-report measure of stigma among MSM. The scale has three subscales: enacted stigma (7 items, rated 1 [never] to 4 [many times]), perceived stigma (11 items), and internalized stigma (8 items). Perceived and internalized stigma items are rated 1 (strongly disagree) to 4 (strongly agree). Each subscale score is the mean of its items and ranges from 1 to 4. Higher scores indicate greater stigma. Change is calculated as the 3-month and 6- month score minus the baseline score.

Baseline, 3 months, and 6 months
Change in observed HIV-related stigma in healthcare settings
Prazo: Baseline, 3 months, and 6 months

Change in observed HIV-related stigma will be measured using 3 items assessing HIV-related stigma among health facility staff. Items ask how often participants observed stigmatizing behaviors in their health facility in the past 12 months (for example, health workers unwilling to care for a patient living with HIV). Each item is rated on a 4-point frequency scale: 1 (never), 2 (once or twice), 3 (several times), and 4 (most of the time). The score is the sum of the 3 items and ranges from 3 to 12. Higher scores indicate more observed stigma.

Baseline, 3 months, and 6 months

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Toan Ha, MD, DrPH, University of Pittsburgh

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

1 de abril de 2027

Conclusão Primária (Estimado)

15 de julho de 2027

Conclusão do estudo (Estimado)

1 de março de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

13 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

13 de novembro de 2026

Primeira postagem (Real)

18 de novembro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

13 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Termos MeSH relevantes adicionais

Outros números de identificação do estudo

  • STUDY26010095
  • R01TW013193 (Concessão/Contrato do NIH dos EUA)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

De-identified individual participant data (IPD) underlying the results reported in publications will be deposited in an NIH-supported repository for HIV-related behavioral research. Access will be controlled and subject to a data use agreement prohibiting re-identification and unauthorized disclosure. Given the sensitive nature of HIV-related information and sexual orientation, and the risk of re-identification in small samples, data will be reviewed and de-identified before sharing. Data will be made available in accordance with repository policies and applicable consent, ethical, and institutional requirements, for as long as the repository maintains the data and makes them available.

Prazo de Compartilhamento de IPD

Data underlying published results will be available upon publication. Any other Aim 2 data will be shared by the end of the award period at the latest. Data will remain available in the repository for a minimum of 7 years.

Critérios de acesso de compartilhamento IPD

Data will be available free of charge through the Mendeley Data repository. Users must register with the repository and agree to its terms, which restrict use to scientific research and aggregate statistical reporting. Data will be findable through a digital object identifier assigned by the repository. Access will follow the informed consent and institutional requirements, and any data designated as restricted use will be available under the repository's restricted-access terms.

Tipo de informação de suporte de compartilhamento de IPD

  • SEIVA

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Não

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .